Abstract: Enhancing the delivery of therapeutic, diagnostic and other useful compounds to the brain and other tissues permits more effective use of reagents and use of lower doses. Our method permits enhanced delivery of molecules that are diagnostically, therapeutically, or otherwise useful to specific tissues in the body, including the central nervous system (CNS). Large, hydrophilic molecules, such as antibodies, are typically restricted from entering the CNS by the blood-brain barrier and fail to accumulate to therapeutic levels within the brain. Our method permits enhanced penetrance of the CNS by peripherally administered antibodies. Our method can be applied to enhance the delivery of a variety of therapeutic, diagnostic, and otherwise useful molecules to any tissue, many of which have previously been clinically ineffective due to poor tissue penetrance.

Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.

Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.

Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These may be used as therapeutic agents.

Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.